

## 個人履歷

### 基本資料

姓名 東雅惠 (Yaa-Hui Dong)  
住址 臺北市北投區立農街二段 155 號 生物醫學大樓乙棟 214 室  
電話 02-28267000 ext 7986  
電子郵件 [ydong3@ym.edu.tw](mailto:ydong3@ym.edu.tw)

### 研究專長

藥物流行病學  
健康照護資料分析  
系統回顧與統合分析

### 學歷

2008~2012	臺大流行病學與預防醫學研究所	博士
1999~2001	臺大藥學研究所醫院藥學組	碩士
1994~1998	臺大藥學系	學士

### 現職及工作經歷

2021~	陽明交通大學藥學系	副教授
2016~2021	陽明大學藥學系	助理教授
2014~2016	Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, US	Post-doctoral Research Fellow
2013~2014	國泰綜合醫院汐止分院藥劑科	諮詢藥師 (兼職)
2012~2013	臺大健康資料研究中心	博士後研究員
2003~2008	國泰綜合醫院藥劑科	藥師

2003	中華景康藥學基金會	研究助理
2002~2003	和信治癌中心醫院藥劑科	藥師
2001~2002	臺大臨床藥學研究所	助教
1998~1999	馬偕紀念醫院藥劑科	藥師

## 榮譽

2019~2021	陽明大學藥物科學院教師學術卓越獎勵
2018~2019	陽明大學紀念沈力揚教授講師級研究與進修獎助
2016~2018	科技部補助大專校院延攬特殊優秀人才
2016	Best Reviewer of Pharmacoepidemiology and Drug Safety
2013	Scholarship of Postdoctoral Research Abroad Program, National Science Council, Taiwan
2013	Scholarship of International Conference on Pharmacoepidemiology & Therapeutic Risk Management
2012	Member of the Phi Tau Phi Scholastic Honor Society of the Republic of China
2006	Scholarship of Taiwan Fujisawa Foundation

## 著作目錄

(\*corresponding author, #equal contribution)

### 期刊論文

1. **Dong YH\***, Chang CH\*, Wang JL, Wu LC, Lin JW, Toh S (2020, Sep). Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. *JAMA Intern Med*, 2020;180:1587-95.
2. Shin A, Park EH, **Dong YH**, Ha YJ, Lee YJ, Lee EB, Song YW, Kang EH\* (2020, Nov). Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. *Osteoporos Int*, 2020;31:2131-9.
3. **Dong YH**, Wang SV, Gagne JJ, Wu LC, Chang CH\* (2020, Feb). Comparison of different case-crossover variants in handling exposure-time trend or persistent-user bias: using dipeptidyl peptidase-4 inhibitors and the risk of heart failure as an example. *Value in Health*, 2020;23:217-26.
4. Zhan ZW, Chen YA, **Dong YH\*** (2020, Feb). Comparative performance of comorbidity measures in predicting health outcomes in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*, 2020;15:335-44.
5. Chang TY, Chien JY, Wu CH, **Dong YH**, Lin FJ\* (2020, May). Comparative safety and effectiveness of inhaled corticosteroid and long-acting  $\beta$ 2-agonist combinations in patients with COPD. *Chest*, 2020;157:1117-29.
6. Lee YC, Wang JL\*, **Dong YH**, Chen HC, Wu LC, Chang CH\* (2019, Sep). Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: a cohort study. *PLoS Med*, 2019; 16:e1002894.
7. Lin HD, Lai CL, **Dong YH**, Tu YK, Chan KA\*, Suissa S (2019, Jun). Re-evaluating Safety and effectiveness of dabigatran versus warfarin in a nationwide data environment: a prevalent new-user design study. *Drugs- Real World Outcomes*, 2019;6:93-104.
8. Wang JL#, **Dong YH#**, Ko WC\*, Chang CH\*, Wu LC, Chuang LM, Chen PC (2018, Dec). Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study. *Diabetes Obes Metab*, 2018;20:2811-20.
9. Kumamaru H, Lee MP, Choudhry NK, **Dong YH**, Krumme AA, Khan N, Brill G, Kohsaka S, Miyata H, Schneeweiss S, Gagne JJ\* (2018, Nov). Using previous

- medication adherence to predict future adherence. *J Manag Care Spec Pharm*, 2018;24:1146-55.
10. **Dong YH**, Chang CH\*, Wu LC, Hwang JS, Toh S (2018, May). Comparative cardiovascular safety of non-steroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. *Br J Clin Pharmacol*, 2018;84:1045-56.
  11. **Dong YH**, Jin Y, Tsacogianis TN, He M, Hsieh PH, Gagne JJ\* (2018, Mar). Use of olmesartan and enteropathy outcomes: a multi-database study. *Aliment Pharmacol Ther*, 2018;47:792-800.
  12. **Dong YH**, Choudhry NK, Krumme A, Lee MP, Wu LC, Lai MS\*, Gagne JJ (2017, Jun). Impact of hospitalization on medication adherence estimation in claims data. *J Clin Pharm Ther*, 2017;42:318-28.
  13. **Dong YH**, Bykov K, Choudhry NK, Donneyong MM, Huybrechts KF, Levin R, Schneeweiss S, Gagne JJ\* (2017, Apr). Clinical outcomes of concomitant use of warfarin and selective serotonin reuptake inhibitors: a multidatabase observational cohort study. *J Clin Psychopharmacol*, 2017;37:200-9.
  14. **Dong YH**, Alcusky M, Maio V, Liu J, Liu M, Wu LC, Chang CH\*, Lai MS, Gagne JJ (2017, Mar). Evidence of potential bias in a comparison of  $\beta$  blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. *BMJ Open*, 2017;7:e012997.
  15. Bykov K, Schneeweiss S, Donneyong MM, **Dong YH**, Choudhry NK, Gagne JJ\* (2017, Feb). Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. *Am J Cardiol*, 2017;15:119:651-7.
  16. Lee YC, Chang CH\*, **Dong YH**, Lin JW, Wu LC, Hwang JS, Chuang LM (2017, Feb). Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. *Int J Cardiol*, 2017;228:1007-14.
  17. **Dong YH**, Chang CH\*, Wu LC, Lai MS (2016, Oct). Use of cardioselective  $\beta$ -blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study. *Eur J Clin Pharmacol*, 2016;72:1265-73.
  18. Donneyong MM, Bykov K, Bosco-Levy P, **Dong YH**, Levin R, Gagne JJ\* (2016, Sep). Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. *BMJ*, 2016;354:i5014.
  19. Lo Y, Shen LJ, Chen WH, **Dong YH**, Wu FL\* (2016, Sep). Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis. *J Formos Med Assoc*, 2016;115:744-51.
  20. **Dong YH**, Chang CH\*, Gagne JJ, Hsu CL, Lai MS (2016, Jan). Comparative

- cardiovascular and cerebrovascular safety of bronchodilators in patients with chronic obstructive pulmonary disease: a population-based cohort study. *Pharmacotherapy*, 2016;36:26-37.
21. **Dong YH#**, Hsu CL#, Li YY, Chang CH\*, Lai MS (2015, Sep). Bronchodilators use in patients with COPD. *Int J Chron Obstruct Pulmon Dis*, 2015;10:1769-79.
  22. Weng TC#, Chang CH#, **Dong YH**, Chang YC, Chuang LM\* (2015, Jul). Anemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. *BMJ Open*, 2015;5:e006964.
  23. **Dong YH**, Chang CH\*, Mahler DA (2014, Dec). Response: secondary outcomes and Peto OR in meta-analysis. *Chest*, 2014;146:e212-3.
  24. **Dong YH**, Lin JW, Wu LC, Chen CY, Chang CH\*, Chen KY, Lai MS (2014, Dec). Examining the association between statins and lung cancer incidence in patients with type 2 diabetes mellitus. *J Formos Med Assoc*, 2014;113:940-8.
  25. Chen GL#, Hsiao FY#, **Dong YH**, Shen LJ\*, Wu FL\* (2014, Jul). Statins and the risk of liver injury: a population-based case-control study. *Pharmacoepidemiol Drug Saf*, 2014;23:719-25.
  26. **Dong YH#**, Chang CH#, Wu FL, Shen LJ, Calverley PMA, Löfdahl CG, Lai MS\*, Mahler DA (2014, Jun). Use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease and the risk of tuberculosis and influenza: a systematic review and meta-analysis of randomized controlled trials. *Chest*, 2014;145:1286-97.
  27. **Dong YH**, Chang CH, Shau WY, Kuo RN, Lai MS\*, Chan KA\* (2013, Feb). Development and validation of a pharmacy-based comorbidity measure in a population-based automated healthcare database. *Pharmacotherapy*, 2013;33:126-36.
  28. **Dong YH**, Lin HH, Shau WY, Wu YC, Chang CH\*, Lai MS\* (2013, Jan). Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. *Thorax*, 2013;68:48-56..
  29. Lascelles BD\*, **Dong YH**, Marcellin-Little DJ, Thomson A, Wheeler S, Correa M (2012, Jan). Relationship of orthopedic examination, goniometric measurements, and radiographic signs of degenerative joint disease in cats. *BMC Vet Res*, 2012;8:10.
  30. Kuo RN, **Dong YH**, Liu JP, Chang CH, Shau WY, Lai MS\* (2011, Nov). Predicting healthcare utilization using a pharmacy-based metric with the WHO's Anatomic Therapeutic Chemical algorithm. *Med Care*, 2011;49:1031-9..
  31. 張意宜、江村煌、**東雅惠\***。某區域醫院病人使用含碘顯影劑產生立即性不良反應之研究。臺灣臨床藥學雜誌 2013，21 卷 2 期。頁 1-10。

32. 東雅惠、黃婉翠、林惜燕\*。介紹日本醫院藥局藥事服務-以九州大學附設醫院藥劑部為例。藥學雜誌 2009，25 卷 3 期。頁 72-4。
33. 東雅惠、林惜燕\*。談日本病院藥劑管理指導-以九州大學附設病院藥劑部為例。藥學雜誌 2007，23 卷 4 期。頁 12-5。
34. 東雅惠、黃婉翠、方信智、吳淑英、黃政華、徐志育、林惜燕\*。某醫學中心門診病人上呼吸道感染抗生素使用之改善措施及其影響。臺灣家庭醫學研究 2007，5 卷 3 期。頁 97-107。